Key facts
- This page summarizes Bryan K. Gathagan's Form 4 filing for IMMUCELL CORP /DE/ (ICCC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Apr 2026, 15:40.
Bryan K. Gathagan - 16 Apr 2025 Form 4 Insider Report for IMMUCELL CORP /DE/ (ICCC)
- Reporting relationship
- Director
- Issuer ticker
- ICCC
- Reported as of
- 16 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Apr 2026, 15:40:19 UTC
- Prior SEC filing
- 24 Sep 2024
- Next SEC filing
- 12 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Fiori Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bryan K. Gathagan filed Form 4 for IMMUCELL CORP /DE/ (ICCC) on 14 Apr 2026.
Change
- Previous filing in this sequence was filed on 24 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001981919
Primary reporting owner
Gathagan Bryan K.
- Relationship
- Director
- Address
- C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND
- Signature
- /s/ Timothy C. Fiori Attorney-in-Fact
- Signature date
- 14 Apr 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICCC
transaction
Derivative
Non Qualified Stock Options (Right to buy)
Award
- Transaction value
- Shares
- +10,000
- Change %
- Price
- $0.000000*
- Shares after
- 10,000
- Date
- 16 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $5.49
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.